Literature DB >> 16026236

Clinical assessment and treatment of attention deficit hyperactivity disorder in adults.

Philip Asherson1.   

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common childhood disorder that frequently persists into adulthood, with significant levels of inattentive, hyperactive and impulsive behavior. Impairments associated with adult ADHD include distress from the symptoms, impaired ability to function in work and academic settings, and problems sustaining stable relationships. The disorder is commonly associated with volatile moods, antisocial behavior, and drug and alcohol misuse. There is an increased risk of developing comorbid anxiety, depression, personality disorders, and drug and alcohol dependence. Despite the proven effectiveness of drugs such as methylphenidate, dexamphetamine and atomoxetine, few cases of ADHD are recognized and treated in the UK. The reasons for this are unclear, since most psychiatrists working with children and adolescents are aware that ADHD commonly persists into adult life and they also see the disorder affecting parents of children with ADHD. Issues of transition from the care of child to adult psychiatry and the need to refer adult relatives of children with ADHD to suitable psychiatric services are a major concern. Furthermore, many cases of adult ADHD go unrecognized or are seen by mental health teams that are not familiar with the subtleties of the adult presentation. As a result, misdiagnosis and treatment for conditions such as atypical depression, mixed affective disorder, cyclothymia, and borderline and unstable emotional personality disorders is not uncommon. There is therefore a requirement for further training in this area. This review will describe the common clinical presentation and provide guidelines for the diagnosis and treatment of ADHD in adults. Any psychiatrically trained physician using standard psychiatric assessment procedures can perform clinical evaluations for adult ADHD. As with other psychiatric disorders in adulthood, ADHD has its own characteristic onset, course and psychopathology. Symptoms of ADHD are trait-like, being stable characteristics from early childhood, and commonly co-occur with affective instability. Stimulants are the mainstay of treatment and are effective in around 70% of cases. Psychotherapeutic interventions also have an important role. These guidelines will assist psychiatrists and other adult mental health workers in identifying and treating individuals with adult ADHD.

Entities:  

Mesh:

Year:  2005        PMID: 16026236     DOI: 10.1586/14737175.5.4.525

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  39 in total

1.  Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults.

Authors:  Nirit Agay; Eldad Yechiam; Ziv Carmel; Yechiel Levkovitz
Journal:  Psychopharmacology (Berl)       Date:  2010-04-28       Impact factor: 4.530

2.  Different heritabilities but shared etiological influences for parent, teacher and self-ratings of ADHD symptoms: an adolescent twin study.

Authors:  A Merwood; C U Greven; T S Price; F Rijsdijk; J Kuntsi; G McLoughlin; H Larsson; P J Asherson
Journal:  Psychol Med       Date:  2013-01-09       Impact factor: 7.723

Review 3.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

4.  The association between the catechol-O-methyltransferase Val108/158Met polymorphism and hyperactive-impulsive and inattentive symptoms in youth.

Authors:  Matea Nikolac Perkovic; Evelyn Kiive; Gordana Nedic Erjavec; Toomas Veidebaum; Mario Curkovic; Katarina Dodig-Curkovic; Dorotea Muck-Seler; Jaanus Harro; Nela Pivac
Journal:  Psychopharmacology (Berl)       Date:  2013-05-29       Impact factor: 4.530

Review 5.  Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis.

Authors:  Kim Peterson; Marian S McDonagh; Rongwei Fu
Journal:  Psychopharmacology (Berl)       Date:  2007-11-17       Impact factor: 4.530

Review 6.  Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults.

Authors:  Christopher Gibbins; Margaret Weiss
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

7.  Comorbidities and continuities as ontogenic processes: toward a developmental spectrum model of externalizing psychopathology.

Authors:  Theodore P Beauchaine; Tiffany McNulty
Journal:  Dev Psychopathol       Date:  2013-11

8.  Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride.

Authors:  Rajasree Nair; Shannon B Moss
Journal:  Neuropsychiatr Dis Treat       Date:  2009-08-20       Impact factor: 2.570

9.  Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Authors:  Jan K Buitelaar; J Antoni Ramos-Quiroga; Miguel Casas; J J Sandra Kooij; Asko Niemelä; Eric Konofal; Joachim Dejonckheere; Bradford H Challis; Rossella Medori
Journal:  Neuropsychiatr Dis Treat       Date:  2009-09-15       Impact factor: 2.570

10.  Electrophysiological evidence for abnormal preparatory states and inhibitory processing in adult ADHD.

Authors:  Gráinne McLoughlin; Bjoern Albrecht; Tobias Banaschewski; Aribert Rothenberger; Daniel Brandeis; Philip Asherson; Jonna Kuntsi
Journal:  Behav Brain Funct       Date:  2010-10-28       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.